Cannabis Science (CBIS) Announces Positive Results in California Test Run of Its Pure Decarboxylated CO2 Oil (PDCO) Released Through the Cannabis Science Research Foundation (CSRF) to 15 Dispensaries & Several Less Fortunate, Self-Medicating Patients for
COLORADO SPRINGS, CO--(Marketwired - Nov 25, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced positive results from its initial test run of its Pure Decarboxylated CO2 Oil (PDCO) released through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and several less fortunate self-medicating patients.
This trial, collaborative rollout by CSRF, as contracted by Cannabis Science to the California not-for-profit, was designed to meet two primary goals. The first, to conduct tests on the efficacy of the product for patients; the second, to gather proprietary data based on testimonials from real self-medicating consumers from their firsthand experiences. The feedback received will be used to influence the Company's continuing efforts to bring the best cannabinoid-based formulations to market in multiple regulated jurisdictions.
The CBIS Branded product was distributed to 15 dispensaries in California for testing, but will see a much wider distribution when the compound comes fully to market, particularly given the positive initial results. The Foundation released the Cannabis Science PDCO batch approximately three months ago, selling half the product to California dispensaries while giving the remaining product to less fortunate patients in need of treatment, who demonstrated financial hardship and met the legal criteria for prescription of this cannabis-based formulation under state law.
"It is always amazing to hear when your Company's product has changed a patient's life. We had an overwhelming amount of positive feedback with our PDCO collaborative trial, which was consistent with past experience. Even in such a short time, the oil was able to significantly improve the symptoms of a man who has suffered from Multiple Sclerosis for the past twelve years. It is heartwarming and very encouraging to hear that our outstanding team is changing lives with our product, and that our dispensary customers are so eager to stock our compound," said Cannabis Science CEO and President, Raymond C. Dabney. "While not a part of the trial, we even had some patients give samples of their treatments to their suffering pets with spectacular results. This reinforces our optimistic outlook on our upcoming Equi-Pharm product lines."
With clinical trials on the agenda for the Cannabis Science team, the knowledge obtained with this trial run from self-medicating patients in California will continue to add to the compelling data that drives the process in creating the best products possible. The Company will move forward to continue building the brand and give consumers the confidence they should have in the products they buy and use to improve their health.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
About Cannabis Science Research Foundation
The Cannabis Science Research Foundation, a non-profit organization, is a new source of hope for a world where countless medical conditions affect millions of people in the United States alone. It is not just any foundation; it is an institute bringing new findings about the endocannabinoid system to light using state of the art research. The findings from the research will guide the Foundation to develop new products, enter the FDA, and perform clinical studies.
Cannabis Science Research Foundation has identified numerous ailments that require more research to determine if phytocannabinoids are an appropriate treatment, but show promise in this regard. The Foundation works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.
The Foundation is funded internally and externally through donations and fundraising events. The funds raised support all aspects of the Foundation's research efforts. Events will include concerts, black tie events, charity fundraising events, movie showings, documentaries, and more.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.